A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer.
David B PageJoanna PucilowskaKatherine G SanchezValerie K ConradAlison K ConlinAnupama K AchesonKelly S PerlewitzJames H ImataniShaghayegh Aliabadi-WahleNicole MoxonStaci L MellingerAmanda Y SeinoMartiza MartelYaping WuZhaoyu SunWilliam L RedmondVenkatesh RajamanickamDottie WaddellDeborah LaxagueMonil ShahShu-Ching ChangWalter J UrbaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
IRX-2 is safe in early-stage breast cancer. Potentially favorable immunomodulatory changes were observed, supporting further study of IRX-2 in early-stage breast cancer and other malignancies.